These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with ...
Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full ...
BioAtla, Inc., a biotechnology company specializing in Condition Active Biologic (CAB) antibody therapeutics for solid tumors, announced it will present a poster at the upcoming 2025 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results